Home
Immunome

Immunome Market Share Analysis for May 2026

Health > Biotechnology and Pharmaceuticals

Domainimmunome.com

Year Founded2006

Employees51 - 200

Annual Revenue$5M - $10M

Immunome

Immunome (including company regionals)

immunome.com

See more website traffic and engagement information

Immunome Revenue up to May 2026 is 5M - 10M

revenue generated by Immunome top domains

Immunome top domains revenue over 3 years

Revenue for Immunome top domains

immunome.com5M - 10M

See more with Sales Intelligence

Total visits to Immunome's top domains

Understand Immunome market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

immunome.com9.7K

See more with Sales Intelligence

Avg. visit duration in Immunome's top domains

Analyze Immunome engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

immunome.com00:00:28

See more with Sales Intelligence

Avg. pageviews on Immunome's top domains

See how Immunome keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

immunome.com1.84

See more with Sales Intelligence

Immunome top competitors by domain

Top similar sites in May 2026, ranked by their affinity

shattucklabs.comCompany NameShattuck LabsEmployees51 - 200HQUnited States, Texas, AustinAnnual revenue$1M - $2MTotal visits5.1KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Immunome

These are the website technologies, by industry, used by Immunome top domains

Widget (4)

Twemoji

Content Management System (3)

WordPress

Conversion & Analytics (3)

Google Analytics

Email Services (3)

G Suite

More Technologies

8

See all

News & Signals from Immunome

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsImmunome, Inc. launched first-in-class ADC targeting mystery immune-excluding receptor tyrosine kinase on Jun 12th '26.Immunome debuts first-in-class ADC targeting mystery immune-excluding receptor tyrosine kinase.

NewsImmunome, Inc. is developing varegacestat on Apr 29th '26.BOTHELL, Wash. April 29, 2026 - Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors.

NewsImmunome, Inc. will attend event 2026 Annual Meeting on Jun 9th '26.Immunome, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 9, 2026 at 12:00 p.m. Eastern Time.